Myriad Genetics was a winner within the diversified services industry, rising $0.74 (1.8%) to $40.99 on heavy volume

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Myriad Genetics ( MYGN) pushed the Diversified Services industry higher today making it today's featured diversified services winner. The industry as a whole closed the day down 1.9%. By the end of trading, Myriad Genetics rose $0.74 (1.8%) to $40.99 on heavy volume. Throughout the day, 3,844,740 shares of Myriad Genetics exchanged hands as compared to its average daily volume of 2,236,800 shares. The stock ranged in a price between $40.80-$42.50 after having opened the day at $42.10 as compared to the previous trading day's close of $40.25. Other companies within the Diversified Services industry that increased today were: Synnex Corporation ( SNX), up 23.3%, Swisher Hygiene ( SWSH), up 5.3%, USA Technologies ( USAT), up 5.0% and EnviroStar ( EVI), up 4.7%.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Myriad Genetics has a market cap of $2.9 billion and is part of the services sector. Shares are up 91.8% year to date as of the close of trading on Thursday. Currently there are 3 analysts that rate Myriad Genetics a buy, 2 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Myriad Genetics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.